Drugs & Targets FDA approves durvalumab for muscle invasive bladder cancer April 04, 2025Vol.51 No.13
Capitol Hill Kennedy announces massive cuts, centralization at HHS—NCI and FDA hitAlso this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology March 28, 2025Vol.51 No.12By Claire Marie Porter and Jacquelyn Cobb
Drugs & Targets FDA approves cabozantinib for patients 12 and up with pNET and epNET March 28, 2025Vol.51 No.12
Drugs & Targets FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1) March 21, 2025Vol.51 No.11
Drugs & Targets FDA grants Orphan Drug designation to rhenium obisbemeda for leptomeningeal metastases in lung cancer March 14, 2025Vol.51 No.10
Clinical Roundup CAR T-cell therapy for B-ALL results in high incidence of durable response in phase I/II study March 07, 2025Vol.51 No.09
Clinical Roundup Rusfertide meets primary endpoint in phase III VERIFY trial for patients with polycythemia vera March 07, 2025Vol.51 No.09
Guest Editorial Biomarker-driven innovation: What the FDA’s evolving strategy means for oncology February 28, 2025Vol.51 No.08By Harpreet Singh
